Primary Care Issues for HIV-Infected Patients

Infectious Disease Clinics of North America

Volumn 21, Issue 1, 2007, Pages 49-70

  Cohen, Daniel E ^a,b   Mayer, Kenneth H ^a,c  

^a FENWAY INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; FENOFIBRATE; GEMFIBROZIL; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B VACCINE; PRAVASTATIN; TUBERCULOSTATIC AGENT;

CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; HEALTH PROMOTION; HEPATITIS; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNIZATION; LABORATORY TEST; MALE HOMOSEXUAL; MEDICAL SERVICE; MEDICAL SPECIALIST; MENTAL DISEASE; PAPANICOLAOU TEST; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PHYSICAL EXAMINATION; PNEUMOCYSTIS PNEUMONIA; PRIMARY MEDICAL CARE; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; RISK REDUCTION; SEXUALLY TRANSMITTED DISEASE; SOCIAL CARE; STIGMA; SUBSTANCE ABUSE; SYMPTOMATOLOGY; SYPHILIS; TUBERCULOSIS; WART VIRUS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; RISK FACTORS; SAFE SEX;

EID: 34248574893     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.01.001     Document Type: Review

References (50)

1. Kitahata M.M., Van Rompaey S.E., Dillingham P.W., et al. Primary care delivery is associated with greater physician experience and improved survival among persons with AIDS. J Gen Intern Med 18 2 (2003) 95-103
2. Taylor Z., Nolan C.M., and Blumberg H.M. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 54 RR-12 (2005) 1-81
3. Lee L.S., Andrade A.S., and Flexner C. Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin Infect Dis 43 8 (2006) 1052-1059 [Epub Sep 8, 2006]
4. Piscitelli S.C., Burstein A.H., Chaitt D., et al. Indinavir concentrations and St. John's wort. Lancet 355 9203 (2000) 547-548
5. Goldie S.J., Freedberg K.A., Weinstein M.C., et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 111 2 (2001) 140-149
6. Goldie S.J., Kuntz K.M., Weinstein M.C., et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 281 19 (1999) 1822-1829
7. Holly E.A., Ralston M.L., Darragh T.M., et al. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 93 11 (2001) 843-849
8. Hillemanns P., Ellerbrock T.V., McPhillips S., et al. Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women. AIDS 10 14 (1996) 1641-1647
9. Hadigan C., Meigs J., Corcoran C., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32 1 (2001) 130-139
10. Crowe S.M., Carlin J.B., Stewart K.I., et al. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 4 8 (1991) 770-776
11. Lyles R.H., Munoz A., Yamashita T.E., et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 181 3 (2000) 872-880
12. Mellors J.W., Rinaldo Jr. C.R., Gupta P., et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. [see comments] [published erratum appears in Science 1997 Jan 3;275(5296):14]. Science 272 5265 (1996) 1167-1170
13. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed October 10, 2006.
14. Hammer S.M., Saag M.S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 7 (2006) 827-843
15. Kaplan J.E., Masur H., and Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 51 RR-8 (2002) 1-52
16. Workowski K.A., and Berman S.M. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55 RR-11 (2006) 1-94
17. Palefsky J.M. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 15 5 (2003) 382-388
18. Palefsky J.M., Holly E.A., Efirdc J.T., et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 19 13 (2005) 1407-1414
19. Chin-Hong P.V., and Palefsky J.M. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol Ther 18 1 (2005) 67-76
20. Wright T.C., Cox J.T., Massad L.S., et al. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287 16 (2002) 2120-2129
21. Palefsky J.M., Holly E.A., Hogeboom C.J., et al. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 14 5 (1997) 415-422
22. Chiao E.Y., Giordano T.P., Palefsky J.M., et al. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 43 2 (2006) 223-233
23. Gunthard H.F., Wong J.K., Spina C.A., et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 181 2 (2000) 522-531
24. Tasker S.A., O'Brien W.A., Treanor J.J., et al. Effects of influenza vaccination in HIV-infected adults: a double- blind, placebo-controlled trial. Vaccine 16 9-10 (1998) 1039-1042
25. Macias J., Pineda J.A., Leal M., et al. HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination. Eur J Clin Microbiol Infect Dis 20 1 (2001) 46-48
26. Broder K.R., Cortese M.M., Iskander J.K., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-3 (2006) 1-34
27. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 48 RR-10 (1999) 1-66
28. DiRienzo A.G., van Der Horst C., Finkelstein D.M., et al. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses 18 2 (2002) 89-94
29. Blumberg H.M., Leonard M.K., and Jasmer R.M. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 293 22 (2005) 2776-2784
30. Centers for Disease Control. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 52 RR-12 (2003) 1-24
31. Gray R.H., Wawer M.J., Brookmeyer R., et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357 9263 (2001) 1149-1153
32. Gray R.H., Kiwanuka N., Quinn T.C., et al. Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS 14 15 (2000) 2371-2381
33. Vittinghoff E., Douglas J., Judson F., et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 150 3 (1999) 306-311
34. Dillon B, Hecht FM, Swanson M, et al. Primary HIV infections associated with oral transmission. Presented at the 7th Annual Conference on Retroviruses and Opportunistic Infections. San Francisco, January 30-February 2, 2000.
35. Vernazza P.L., Gilliam B.L., Dyer J., et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 11 8 (1997) 987-993
36. Vernazza PL. HIV/STDs and excretions of HIV in genital secretions: implications for sexual transmission [abstract 128]. Program and Abstracts of the Infectious Diseases Society of America 2004 Annual Meeting. Boston, Massachusetts, September 30-October 3, 2004.
37. Searight H., and McLaren A. Behavioral and psychiatric aspects of HIV infection. Am Fam Physician 55 4 (1997) 1227-1242
38. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 7 (1998) F51-F58
39. Behrens G., Dejam A., Schmidt H., et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13 10 (1999) F63-F70
40. Mulligan K., Grunfeld C., Tai V.W., et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23 1 (2000) 35-43
41. Henry K., Melroe H., Huebsch J., et al. Severe premature coronary artery disease with protease inhibitors. Lancet 351 9112 (1998) 1328
42. Friis-Moller N., Sabin C.A., Weber R., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 21 (2003) 1993-2003
43. Dube M.P., Stein J.H., Aberg J.A., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37 5 (2003) 613-627 [Epub Aug 15, 2003]
44. Paterson D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133 1 (2000) 21-30
45. Bangsberg D.R. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 43 7 (2006) 939-941 [Epub Aug 23, 2006]
46. Wood E., Hogg R.S., Yip B., et al. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 35 3 (2004) 261-268
47. Glass T.R., De Geest S., Weber R., et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 41 3 (2006) 385-392
48. Holzemer W.L., Corless I.B., Nokes K.M., et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 13 3 (1999) 185-197
49. Singh N., Squier C., Sivek C., et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 8 3 (1996) 261-269
50. Bangsberg DR, Perry S, Charlebois ED, et al. Depression symptoms (DS) predict HAART adherence, duration, unstructured treatment interruption and viral suppression [abstract I-1721]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, Illinois, December 16-19, 2001.